Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Current Hypertension Reports
Erschienen in: Current Hypertension Reports 7/2016

01.07.2016 | Guidelines/Clinical Trials/Meta-Analysis (J Kostis, Section Editor)

Renal Denervation: a Field in Flux

verfasst von: Luke J. Laffin, George L. Bakris

Erschienen in: Current Hypertension Reports | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

SYMPLICITY HTN-3 was a pivotal moment for renal denervation as a treatment option for resistant hypertension. Prior unblinded studies were called into question given the negative results of the first sham-controlled trial of renal denervation. Reevaluation of the renal denervation procedure demonstrated that a more precise approach was needed to adequately denervate the kidney. This new approach has been implemented in two ongoing clinical trials, one on and one off medications to assess the new procedure’s efficacy and safety. These and other ongoing trials will be discussed in the context of older studies in this field. We focus on novel findings published following the release of SYMPLICITY HTN-3 data in early 2014 and look to the future of renal denervation in the treatment of primary hypertension.
Literatur
1.•
Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401. Only major sham-controlled trial of renal denervation. It did not demonstrate any difference between renal denervation and sham procedure with respect to office blood pressure.CrossRefPubMed
2.
Papademetriou V, Tsioufis C, Doumas M. Renal denervation and Symplicity HTN-3: “Dubium sapientiae initium” (doubt is the beginning of wisdom). Circ Res. 2014;115(2):211–4.CrossRefPubMed
3.
Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593–8.CrossRefPubMed
4.
Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.CrossRef
5.
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.CrossRefPubMed
6.
Group SR, Wright Jr JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef
7.
8.
Laffin LJ, Bakris GL. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015;21:20–4.CrossRefPubMed
9.
Bakris GL, Townsend RR, Liu M, Cohen SA, D’Agostino R, Flack JM, et al. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3. J Am Coll Cardiol. 2014;64(11):1071–8.CrossRefPubMed
10.••
Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D’Agostino R, et al. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial. J Am Coll Cardiol. 2015;65(13):1314–21. 12-month ambulatory and office blood pressure results from SYMPLICITY HTN-3. Data support no further reduction in office or ambulatory BP after 1-year of follow-up.CrossRefPubMed
11.
Lambert T, Nahler A, Reiter C, Schwarz S, Gammer V, Blessberger H, et al. Frequency of renal artery stenosis after renal denervation in patients with resistant arterial hypertension. Am J Cardiol. 2015;115(11):1545–8.CrossRefPubMed
12.
Schmid A, Schmieder R, Lell M, Janka R, Veelken R, Schmieder RE, et al. Mid-term vascular safety of renal denervation assessed by follow-up MR imaging. Cardiovasc Intervent Radiol. 2016;39(3):426–32.CrossRefPubMed
13.
Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635–43.CrossRefPubMed
14.
Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–27.CrossRefPubMed
15.••
Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol. 2015;66(16):1766–75. Preclinical porcine model of renal denervation established following negative results of SYMPLICITY HTN-3 that characterizes the types of ablations needed to maximally decrease norepinephrine levels and renal vasculature axon density.CrossRefPubMed
16.
Messerli FH, Bangalore S. Renal denervation for resistant hypertension? N Engl J Med. 2014;370(15):1454–7.CrossRefPubMed
17.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059–68.CrossRefPubMedPubMedCentral
18.
Rosa J, Widimsky P, Tousek P, Petrak O, Curila K, Waldauf P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 Study. Hypertension. 2015;65(2):407–13.CrossRefPubMed
19.
Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 Study. Hypertension. 2016;67(2):397–403.PubMed
20.
Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65.CrossRefPubMed
21.••
Sun D, Li C, Li M, Liu J, Wen S. Renal denervation vs pharmacotherapy for resistant hypertension: a meta-analysis. J Clin Hypertens (Greenwich). 2015. doi:10.​1111/​jch.​12742. Meta-analysis of 9 renal denervation versus pharmacotherapy trials in resistant hypertension, of which 6 were randomized. When only accounting for 6 randomized trials there was no difference in blood pressure lowering with renal denervation versus pharmacotherapy.
22.•
Bohm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, et al. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. Hypertension. 2015;65(4):766–74. First published data from a prospective registry created to document the long-term safety and effectiveness of renal denervation in a real world patient population with hypertension. It also aims to gather data for other diseases characterized by elevated sympathetic drive.CrossRefPubMed
23.
Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33.CrossRefPubMed
24.
Hyman DJ, Pavlik V. Medication adherence and resistant hypertension. J Hum Hypertens. 2015;29(4):213–8.CrossRefPubMed
25.
Ricke J, Seidensticker M, Becker S, Schiefer J, Adamchic I, Lohfink K, et al. Renal sympathetic denervation by CT-guided ethanol injection: a phase II pilot trial of a novel technique. Cardiovasc Intervent Radiol. 2016;39(2):251–60.CrossRefPubMed
Metadaten
Titel
Renal Denervation: a Field in Flux
verfasst von
Luke J. Laffin
George L. Bakris
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Current Hypertension Reports / Ausgabe 7/2016
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-016-0666-1

Weitere Artikel der Ausgabe 7/2016

Current Hypertension Reports 7/2016 Zur Ausgabe

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Obstructive Sleep Apnoea and Hypertension: the Role of the Central Nervous System

Preeclampsia (VD Garovic, Section Editor)

Aspirin vs Heparin for the Prevention of Preeclampsia

Therapeutic Trials (M Weir, Section Editor)

New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease

Resistant Hypertension (E Pimenta, Section Editor)

Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients

Device-Based Approaches for Hypertension (M Schlaich, Section Editor)

Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies

Secondary Hypertension: Nervous System Mechanisms (M Wyss, Section Editor)

Obesity-Induced Hypertension: Brain Signaling Pathways

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise